Study on Molecular Templates’ PD-L1 ETB with Antigen Seeding Technology Presented at SITC Annual Meeting
November 09 2018 - 8:00AM
Antigen Seeding Technology (AST) is a
Potent and Complimentary Addition to Company’s Engineered Toxin
Bodies (ETB) Technology
Molecular Templates, Inc., (Nasdaq: MTEM), a clinical-stage
oncology company focused on the discovery and development of the
company’s proprietary engineered toxin bodies (ETBs), which are
differentiated, targeted, biologic therapeutics for cancer,
announced the presentation today of a poster on its PD-L1 ETB with
Antigen Seeding Technology (AST) at the ongoing Society for
Immunotherapy of Cancer's (SITC) 33rd Annual Meeting,
currently taking place in Washington D.C.
Antigen Seeding Technology represents a novel immune-oncology
approach leveraging the novel mechanism of action of Molecular
Templates’ ETB technology. ETBs engineered with Antigen Seeding
Technology are capable of delivering viral antigens as a payload
inside the target tumor, resulting in the antigens being presented
on the cell surface of the tumor cells in complex with MHC-1. ETB
therapeutics incorporating antigen seeding are designed to work
through dual mechanisms of action by redirecting a high avidity,
pre-existing antigen-specific cytotoxic T cell (CTL) response to
the tumor while at the same inducing cell death via the enzymatic
and permanent destruction of ribosomes. Coupling two distinct
mechanisms of tumor cell killing into one ETB molecule provides the
potential to increase target penetrance, expand a prolonged immune
response, and overcome tumor resistance.
The poster, titled “Identification and Functional Profiling of
PD-L1 Targeted Engineered Toxin Bodies for Antigen Seeding
Technology (AST) and Redirection of T cell Response to Tumors”
summarizes a series of preclinical experiments conducted by
Molecular Templates to create PD-L1 targeted ETBs that have antigen
seeding properties and to analyze the mechanisms by which they can
kill cancer cells.
“Antigen Seeding Technology represents a novel approach to
immune-oncology that may be active in patients where standard
immune-oncology approaches have been exhausted,” said Eric
Poma, Ph.D., Molecular Templates’ Chief Executive and Scientific
Officer. “We are currently conducting in vivo studies with PD-L1
targeted ETBs that have AST functionality. Our plan is to file an
IND and enter the clinic with our first PD-L1 ETB candidate
employing AST in 2019.”
Poster Presentation Details:The poster (#P9)
will be available to view in Hall E of the Walter E. Johnson
Convention Center today, Friday, Nov. 9 from 8 a.m. – 8 p.m. and
Saturday, Nov. 10 from 8 a.m. – 8:30 p.m. (all times are E.T.)
The poster can be found under “Clinical and Scientific
Presentations” at
http://ir.mtem.com/events-and-presentations/presentations.
Forward-Looking StatementsThis press release
contains forward-looking statements for purposes of the Private
Securities Litigation Reform Act of 1995 (the
“Act”). Molecular disclaims any intent or obligation to update
these forward-looking statements, and claims the protection of the
Act’s Safe Harbor for forward-looking statements. All statements,
other than statements of historical facts, included in this press
release regarding strategy, future operations, future financial
position, future revenue, projected expenses, prospects, plans and
objectives of management are forward-looking statements. In
addition, when or if used in this press release, the words “may,”
“could,” “should,” “anticipate,” “believe,” “estimate,” “expect,”
“intend,” “plan,” “predict” and similar expressions and their
variants, as they relate to Molecular, may identify
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating to Molecular’s
expectations with respect to its collaboration with Takeda and its
intended use of proceeds from the offering.
Forward-looking statements are not guarantees of future
performance and involve risks and uncertainties. Actual events or
results may differ materially from those discussed in the
forward-looking statements as a result of various factors
including, but not limited to, the uncertainties inherent in the
preclinical and clinical development process; whether Molecular’s
cash resources will be sufficient to fund its continuing operations
for the periods and/or trials anticipated; the ability of Molecular
to protect its intellectual property rights; and legislative,
regulatory, political and economic developments, as well as those
risks identified under the heading “Risk Factors” in Molecular’s
filings with the SEC. Any forward-looking statements contained
in this press release speak only as of the date hereof, and
Molecular specifically disclaims any obligation to update any
forward-looking statement, whether because of new information,
future events or otherwise.
About Molecular Templates Molecular
Templates is focused on the discovery, development and
commercialization of next-generation immunotoxins called Engineered
Toxin Bodies (ETBs) for the treatment of cancers and other serious
diseases. For additional information, please visit Molecular
Templates’ website at www.mtem.com.
Adam CutlerChief Financial Officeradam.cutler@mtem.com
862-204-4006
Source: Molecular Templates, Inc.
Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From Apr 2023 to Apr 2024